Sanofi Consumer Healthcare India Limited (SCHIL) was established as a distinct legal entity following a strategic demerger from Sanofi India Limited (SIL). Incorporated on May 10, 2023, the demerger of the Consumer Healthcare Division (CHC) business became effective from June 1, 2024, via a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal. This move aligns with Sanofi's global strategy to establish a focused, standalone Consumer Healthcare business.
SCHIL operates in the Consumer Healthcare sector, offering self-care solutions across major health categories, including allergy relief, pain management, and wellness.
Leveraging the extensive global expertise of its parent company, SCHIL aims to enhance consumer well-being through a diversified portfolio spanning multiple health segments:
- Key Therapeutic Segments: Allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements.
- Flagship Brands: Allegra, DePURA, Avil, and Combiflam.
- Other Brands: Festal, Baralgan, and Novalgin NU.
The company utilizes a comprehensive distribution network to reach a wide customer base across India's diverse healthcare market. Its distribution capabilities cover:
- Distributors and Wholesalers
- Government Institutions and Hospitals
- Pharmacies and Pharmacy Chains
- E-commerce platforms
As of the latest available data, Sanofi Consumer Healthcare has a market capitalization of ₹12,371 crore, with annual revenue of ₹668 crore and profit of ₹168 crore (based on latest available annual figures).
Q3 FY25 Performance (Compared to Q3 FY24):
- Net Sales: Increased by 6.8% to ₹170.70 crore.
- Net Profit: Rose 1% to ₹46.35 crore.
- Profit Before Tax (PBT): Stood at ₹62.80 crore, a 2.6% increase from ₹61.20 crore.
The company demonstrates a notably strong financial position:
- Debt Position: Almost debt-free.
- Promoter Holding: 60.4%
- Stock P/E Ratio: 64.8
- Book Value: ₹119
- ROCE (Return on Capital Employed): 111%
- ROE (Return on Equity): 83.8%
- Dividend Yield: 1.04%
- Last 6 Months: +4.08%
- Last 1 Year: +2.3%
- 52-Week High: ₹5,520
- 52-Week Low: ₹4,211.55
The company is primarily owned by its promoter, Opella Healthcare Participations B.V., which holds a 60.4% stake in the total equity. The company's leadership is composed of Amit Jain as the Chairman and Himanshu Bakshi as the Managing Director. There is no promoter pledging in Sanofi Consumer Healthcare India Ltd.
As per the Value Research classification, Sanofi Consumer Healthcare India is categorized as a Small Cap company.
The strategic demerger, which created a focused, independent entity, positions SCHIL to capitalize effectively on India's rapidly growing consumer healthcare sector. Supported by a strong portfolio of established brands (Allegra, Combiflam, etc.), an extensive distribution network, and the backing of the global pharmaceutical giant Sanofi, the company is well-positioned for future growth. The debt-free balance sheet and strong operational metrics further enhance its favorable standing in the competitive Indian healthcare market.
